Inferior vena cava leiomyosarcoma is an exceptionally rare malignant tumour originating from the smooth muscle cells of the inferior vena cava (IVC). Characterised by an insidious onset and ...
W. L. Gore & Associates has secured FDA approval for the GORE VIABAHN FORTEGRA Venous Stent — previously known as the GORE VIAFORT Vascular Stent — the first device for the treatment of deep venous ...
Please provide your email address to receive an email when new articles are posted on . Active surveillance by implanting physicians appeared linked to improved retrieval of inferior vena cava filters ...
The assessment of the inferior vena cava (IVC) and central venous pressure (CVP) has emerged as a pivotal aspect in the optimisation of haemodynamic management across a range of clinical settings.
The Crux retrievable inferior vena cava filter (VCF) represents the first significant innovation in vena cava filters in 40 years. Crux Biomedical designed the device to overcome problems associated ...
The implantation of a novel inferior vena cava (IVC) sensor demonstrated promising safety and feasibility in patients with heart failure, with its measurements showing a strong correlation with those ...
W.L. Gore & Associates announced today that the FDA approved its Viabahn Fortegra venous stent, formerly known as Viafort.
The BCBSA Technology Evaluation Center (TEC) has not conducted an assessment of this technology. Centers for Medicare and Medicaid Services (CMS) A review of the CMS web site did not reveal any ...
In patients with renal cell carcinoma, a phase 2 trial tested neoadjuvant stereotactic ablative radiation therapy to the inferior vena cava tumor thrombus before radical nephrectomy with thrombectomy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback